BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/320/0.1/20.12.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/320/0.1/20.12.24 Stock

DE000VD3R7Q3

Real-time Boerse Frankfurt Warrants 07:43:05 2024-06-27 am EDT
0.088 ^EUR	-36.23%

Current month	-62.70%
1 month	-40.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/320/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	05:28am	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	Jun. 25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	Jun. 24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	Jun. 21	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-27	0.088	-36.23%
24-06-26	0.138	+16.95%
24-06-25	0.118	-7.09%
24-06-24	0.127	-29.05%
24-06-21	0.179	+34.59%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 07:43 am EDT

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3R7Q
ISIN	DE000VD3R7Q3
Date issued	2024-04-09
Strike	320 $
Maturity	2024-12-20 (176 Days)
Parity	10 : 1
Emission price	0.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.14 €
Lowest since issue	0.068 €
Spread	0.034 €
Spread %	24.46%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company